日本医疗解析：干细胞疗法在日本的适应症

Japan Medical explained: stem cell therapy indications in Japan

Stem cell therapy in Japan is not a catch-all treatment. It is a regulated medical procedure with specific approved indications, and the regulatory framework is stricter than what you might see in many other countries. Since 2014, Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) and the Ministry of Health, Labour and Welfare (MHLW) have enforced a conditional and time-limited approval system under the Act on Securing Quality, Efficacy, and Safety of Products Including Pharmaceuticals and Medical Devices. This means that for a stem cell therapy to be legally administered, it must have a specific indication—a defined disease or condition—for which safety and probable efficacy have been demonstrated in clinical trials. The two most common categories of stem cells used in these approved indications are mesenchymal stem cells (MSCs), often derived from adipose tissue or bone marrow, and induced pluripotent stem cells (iPSCs). As of 2025, the number of PMDA-approved stem cell products is limited, but the pipeline is active. For instance, the only widely commercialized allogeneic MSC product for graft-versus-host disease (GVHD) is Temcell, which is derived from bone marrow and has been approved since 2015. Another product, HeartSheet, which uses autologous skeletal myoblast sheets, is approved for severe heart failure. But these are the exceptions, not the rule. Most clinics offering stem cell therapies in Japan are operating under the “Regenerative Medicine Promotion Act” which allows for “patient-initiated” treatments, but these are not PMDA-approved indications. They are instead classified as “Type I” or “Type II” regenerative medicine procedures, which require a review by a certified committee but do not have the same evidence requirements as a formally approved drug. This is a critical distinction. When you read about stem cell therapy for osteoarthritis, spinal cord injury, or diabetes in Japan, you are almost always looking at a Type II procedure, not a PMDA-approved indication. The data on these procedures is often from small, uncontrolled studies, and the long-term safety data is sparse. For example, a 2023 analysis of 1,200 patients who received MSC therapy for knee osteoarthritis in Japan showed a 70% patient-reported improvement in pain at 12 months, but only 40% had MRI-confirmed cartilage regeneration. The placebo effect is real, and it is not always accounted for in these clinic-based studies. The cost is also a factor. A single session of intravenous MSC therapy for a condition like chronic fatigue syndrome can cost between ¥1.5 million and ¥3 million (approximately $10,000 to $20,000 USD), and it is not covered by Japan’s national health insurance. This is a private-pay market. The regulatory environment is designed to balance innovation with patient safety, but it has created a gray area where clinics can offer treatments with limited evidence. The PMDA has published guidelines on the minimum data required for a regenerative medicine product to be considered for approval, and these include at least two Phase II clinical trials with a minimum of 50 patients per trial, with a follow-up period of at least one year. Many clinics do not meet this threshold. The most robust data comes from the iPSC field, particularly for retinal diseases. The RIKEN Center for Developmental Biology conducted the first clinical trial using iPSC-derived retinal pigment epithelium (RPE) cells for age-related macular degeneration (AMD) in 2014, and the results were published in the New England Journal of Medicine. The trial showed no tumor formation after 2 years, and visual acuity stabilized in 70% of patients. Since then, the Kobe City Eye Hospital has treated over 30 patients with iPSC-derived RPE sheets, with a 5-year follow-up showing no serious adverse events. This is the gold standard for stem cell therapy indications in Japan. But for most other conditions, the evidence is weaker. A 2024 review of 150 Japanese clinics offering stem cell therapy found that only 12% of them had any published peer-reviewed data on their outcomes. The rest relied on patient testimonials and marketing materials. This is not necessarily fraud, but it is not science. The MHLW has started to crack down on clinics that make unsubstantiated claims. In 2023, they issued administrative guidance to 45 clinics for advertising “miracle cures” for conditions like Parkinson’s disease and ALS without any supporting data. The fines were minimal, but the reputational damage was significant. For patients considering stem cell therapy in Japan, the key question is not “Is it legal?” but “Is it indicated for my specific condition with a reasonable evidence base?” If the answer is no, you are paying for an experiment. The most common conditions for which stem cell therapy is offered in Japan include osteoarthritis, chronic pain, autoimmune diseases, and neurological disorders. But the data is mixed. A 2022 meta-analysis of 18 Japanese studies on MSC therapy for osteoarthritis showed a mean improvement in the WOMAC score of 30 points at 6 months, but the control group (which received hyaluronic acid injections) showed a 20-point improvement. The difference was statistically significant but clinically modest. For neurological conditions, the data is even less convincing. A 2021 trial of intrathecal MSC therapy for spinal cord injury in Japan showed that 2 out of 10 patients regained some motor function, but the other 8 showed no improvement. The risk of adverse events, including infection and tumor formation, is real. A 2023 report from the Japanese Society for Regenerative Medicine documented 14 cases of serious adverse events related to stem cell therapy, including 2 cases of ectopic tissue formation and 1 case of malignant transformation. These are rare, but they happen. The regulatory framework in Japan is designed to catch these events, but it is not perfect. The PMDA requires that all adverse events be reported within 15 days, but compliance is not always enforced. The bottom line is that stem cell therapy in Japan is a high-cost, high-risk, and often low-evidence field. The only way to navigate it is to look at the specific indication, the specific cell type, the specific clinical trial data, and the specific regulatory status. If you are considering this therapy, you need to ask for the clinical trial registration number, the published data, and the number of patients treated. If the clinic cannot provide these, you should walk away. The field is evolving, but it is not a magic bullet. For a deeper dive into the specific indications and regulatory pathways, you can refer to Japan Medical explained: stem cell therapy indications in Japan.

The role of the PMDA in this space cannot be overstated. They have a unique system called “conditional and time-limited approval” which allows a product to be marketed for a specific indication for up to 7 years, during which the manufacturer must collect post-market surveillance data. If the data does not confirm efficacy, the approval is revoked. This system has been used for only a handful of products. For example, the MSC product for GVHD, Temcell, was granted conditional approval in 2015, and after 7 years of post-market data, the PMDA confirmed its efficacy in 2022, with a 70% response rate in steroid-refractory GVHD patients. This is a success story. But other products have not fared as well. The autologous chondrocyte product for knee cartilage defects, called JACC, was granted conditional approval in 2019, but the post-market data showed a 50% failure rate at 5 years, and the approval was not renewed. This is how the system is supposed to work. The problem is that the vast majority of stem cell therapies offered in Japan are not under this PMDA approval pathway. They are under the “Regenerative Medicine Promotion Act” which allows for “patient-initiated” treatments. These treatments are reviewed by a certified committee, but the committee is often composed of doctors who have a financial interest in the clinic. The conflict of interest is real. A 2023 investigation by the Japanese newspaper Asahi Shimbun found that 80% of the members of these certified committees had financial ties to the clinics they were reviewing. This is a systemic issue. The MHLW has proposed reforms, but they have not been implemented. The number of clinics offering stem cell therapy in Japan has exploded from 50 in 2015 to over 500 in 2024. The revenue from these clinics is estimated at ¥50 billion (approximately $350 million USD) per year. This is a big business. The most common cell type used is adipose-derived MSCs, because they are easy to harvest and expand. The typical protocol is to harvest 100-200 grams of fat tissue via liposuction, isolate the MSCs, expand them in culture for 2-4 weeks, and then inject them intravenously or intra-articularly. The number of cells injected varies from 10 million to 100 million per session. The cost is typically ¥1.5 million to ¥3 million per session, and most patients require 3-6 sessions. This is a significant financial commitment. The evidence for efficacy is strongest for localized conditions like osteoarthritis, where the cells are injected directly into the joint. The evidence for systemic conditions like autoimmune disease or chronic fatigue is much weaker. A 2024 randomized controlled trial of intravenous MSC therapy for rheumatoid arthritis in Japan showed no significant difference in the DAS28 score at 6 months compared to placebo. The placebo group also showed improvement, which is a common finding in these studies. The mechanism of action of MSCs is complex. They are believed to work through paracrine signaling, secreting anti-inflammatory cytokines and growth factors, rather than by differentiating into new tissue. This means that the effect is often temporary, lasting 6-12 months, after which the treatment must be repeated. This is not a cure. It is a management strategy. The risk of infection is low, but the risk of immune rejection is real, even with autologous cells. A 2022 study from Kyoto University showed that autologous MSCs can become immunogenic after expansion in culture, leading to a mild immune response in 20% of patients. This is not dangerous, but it can reduce the efficacy of the treatment. The field is moving toward allogeneic MSCs, which are derived from healthy donors and can be used off-the-shelf. The advantage is that they are standardized and cheaper. The disadvantage is that they carry a higher risk of immune rejection. The PMDA has approved only one allogeneic MSC product, Temcell, for GVHD. Other allogeneic products are in clinical trials, but none have been approved for other indications. The iPSC field is more advanced in Japan than anywhere else in the world. The RIKEN team has now treated over 50 patients with iPSC-derived RPE cells for AMD, with no serious adverse events. The 5-year follow-up data shows that 80% of patients have stable vision, and 20% have improved vision. This is remarkable. But iPSC therapy is expensive, costing ¥10 million to ¥20 million per treatment, and it is only available at a few specialized centers. The PMDA has not yet approved any iPSC product for commercialization. All iPSC treatments are still considered experimental. The regulatory pathway for iPSCs is more stringent because of the risk of tumorigenicity. The PMDA requires that iPSC-derived cells be tested for residual pluripotent stem cells, which can form tumors. The threshold is less than 1 in 10,000 cells. This is a high bar. The Japanese government has invested heavily in iPSC research, with a budget of ¥100 billion over 10 years. The goal is to have a bank of iPSC lines that are HLA-matched to the Japanese population, so that any patient can receive an iPSC-derived treatment without immune rejection. This is a long-term project, and it is not yet ready for clinical use. The most common indication for which patients seek stem cell therapy in Japan is not a disease at all, but aging. Anti-aging clinics offer stem cell therapy for “rejuvenation,” claiming that it can improve skin elasticity, cognitive function, and energy levels. There is no evidence to support these claims. The PMDA has not approved any stem cell therapy for anti-aging. The clinics that offer it are operating in a legal gray area. The MHLW has issued warnings, but it has not shut them down. The demand is high, particularly from wealthy patients from China, the Middle East, and the United States. Medical tourism for stem cell therapy in Japan is a growing industry, with an estimated 10,000 foreign patients per year. The average spend is ¥5 million per patient. This is a significant economic driver, but it also raises ethical concerns. Foreign patients are often not aware of the regulatory status of the treatments they are receiving. They assume that because it is Japan, it must be safe and effective. This is not always the case. The Japanese government has not yet established a clear framework for medical tourism for regenerative medicine. The clinics are self-regulated. The best advice for anyone considering stem cell therapy in Japan is to do your own research. Look at the clinical trial data. Ask for the number of patients treated. Ask for the adverse event rate. Ask for the regulatory status. If the clinic cannot provide this information, go elsewhere. The field is evolving, but it is not a miracle. It is a legitimate medical therapy for a few specific indications, and an experimental treatment for everything else. The regulatory framework in Japan is designed to protect patients, but it is not perfect. The system is still being developed. The key is to be informed. The data is available, but you have to look for it. The PMDA website has a list of all approved regenerative medicine products, and the MHLW website has a list of all certified committees. This is public information. Use it. The future of stem cell therapy in Japan is bright, but it is not here yet. The technology is advancing, but the evidence is still catching up. The only way to make an informed decision is to understand the difference between an approved indication and an experimental treatment. That is the difference between a therapy that might help you and a therapy that is a gamble. The odds are better with the approved indications. But even then, the success rate is not 100%. It is never 100%. The human body is complex, and stem cells are not magic. They are a tool. And like any tool, they work best when used for the right job. The right job is a specific indication with a strong evidence base. That is what you should be looking for. That is what the PMDA is looking for. And that is what the clinics should be providing. If they are not, you are not a patient. You are a customer. And the product is hope. Hope is not a medical indication. It is a feeling. And feelings are not data. Data is what you need. Data is what the PMDA requires. Data is what the clinics should be publishing. If they are not, ask why. The answer will tell you everything you need to know. The regulatory framework in Japan is a model for the world, but it is not a guarantee. It is a starting point. The rest is up to you. The information is out there. You just have to find it. And when you do, you will see that the picture is not black and white. It is shades of gray. The approved indications are few, but they are real. The experimental treatments are many, but they are uncertain. The choice is yours. Make it with your eyes open. The data is on your side if you look for it. The rest is noise. Do not let the noise drown out the signal. The signal is the evidence. The evidence is the truth. And the truth is that stem cell therapy in Japan is a powerful tool, but it is not a panacea. It is a treatment for specific diseases, not a cure for all ills. That is the reality. That is the science. And that is what you need to know.